ArticleScientific reports2025
Temperature-dependent phase transition microemulsions for enhanced transdermal delivery of finasteride and silodosin.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transdermal Drug Delivery Systems: A Comprehensive Review of Mechanisms, Technologies, and Clinical Applications.Pharmaceutical research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Finasteride and silodosin are potential combinations for management of benign prostatic hyperplasia (BPH). Simultaneous transdermal delivery can overcome reasons of their poor oral bioavailability. This was achieved via menthol-based microemulsion (ME) which can undergo thermoresponsive phase transition. Pseudoternary phase diagrams were constructed at room temperature and 32 °C using menthol (oily phase) and Tween 80 (surfactant) in absence and presence of ethanol or propylene glycol as cosurfactants. In absence of cosurfactant, phase behavior depended on temperature with part of liquid crystal (LC) zone changing to microemulsion at 32 °C. Cosurfactant abolished LC/gel zones irrespective to temperature. Microemulsion formulations were selected from the area undergoing LC/ME thermoresponsive transition. These were evaluated for viscosity, droplet size, drug release and skin permeation. Characterization confirmed nanosized droplet and viscosity measurement confirmed thermoresponsive behavior in absence of cosurfactant. MEs showed lower release compared to saturated aqueous solutions. MEs resulted in significant increase in transdermal flux of finasteride and silodosin compared to aqueous control with ethanol containing system producing the highest flux. Simultaneous loading of finasteride and silodosin in microemulsions modulated thermodynamic activity. However, their flux remained significantly higher than aqueous suspension. Thus, the study introduced thermoresponsive microemulsion as efficient system for simultaneous delivery of finasteride and silodosin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.